Biblio
Export 1354 results:
Author Title Type [ Year] Filters: First Letter Of Last Name is P [Clear All Filters]
“Neuroprotective Properties of Eudesmin on a Cellular Model of Amyloid-β Peptide Toxicity.”, J Alzheimers Dis, vol. 94, no. s1, pp. S97-S108, 2023.
, “Neuroprotective Properties of Eudesmin on a Cellular Model of Amyloid-β Peptide Toxicity.”, J Alzheimers Dis, vol. 94, no. s1, pp. S97-S108, 2023.
, “Observed Improvement in Cognition During a Personalized Lifestyle Intervention in People with Cognitive Decline.”, J Alzheimers Dis, vol. 94, no. 3, pp. 993-1004, 2023.
, “Odor Discrimination as a Marker of Early Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. 3, pp. 1169-1178, 2023.
, “Physical Activity for Cognitive Health: A Model for Intervention Design for People Experiencing Cognitive Concerns and Symptoms of Depression or Anxiety.”, J Alzheimers Dis, vol. 94, no. 2, pp. 781-799, 2023.
, “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “Playing Russian Roulette with Alzheimer's Disease Patients: Do the Cognitive Benefits of Lecanemab Outweigh the Risk of Edema, Stroke and Encephalitis?”, J Alzheimers Dis, vol. 92, no. 3, pp. 799-801, 2023.
, “The Potential Role of Selection Bias in the Association Between Coronary Atherosclerosis and Cognitive Impairment.”, J Alzheimers Dis, vol. 93, no. 4, pp. 1307-1316, 2023.
, “The Potential Role of Selection Bias in the Association Between Coronary Atherosclerosis and Cognitive Impairment.”, J Alzheimers Dis, vol. 93, no. 4, pp. 1307-1316, 2023.
, “Proteome Network Analysis Identifies Potential Biomarkers for Brain Aging.”, J Alzheimers Dis, vol. 96, no. 4, pp. 1767-1780, 2023.
, “Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes.”, J Alzheimers Dis, vol. 96, no. 1, pp. 47-56, 2023.
, “Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers.”, J Alzheimers Dis, vol. 94, no. 2, pp. 483-489, 2023.
, “Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study.”, J Alzheimers Dis, vol. 92, no. 2, pp. 653-665, 2023.
, “Serotonin Degeneration and Amyloid-β Deposition in Mild Cognitive Impairment: Relationship to Cognitive Deficits.”, J Alzheimers Dis, vol. 96, no. 1, pp. 215-227, 2023.
, “Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.”, J Alzheimers Dis, vol. 95, no. 1, pp. 213-225, 2023.
, “Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome.”, J Alzheimers Dis, vol. 95, no. 3, pp. 887-899, 2023.
, “Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome.”, J Alzheimers Dis, vol. 95, no. 3, pp. 887-899, 2023.
, “5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 573-585, 2022.
, “Age-Related Oxidative Redox and Metabolic Changes Precede Intraneuronal Amyloid-β Accumulation and Plaque Deposition in a Transgenic Alzheimer's Disease Mouse Model.”, J Alzheimers Dis, vol. 90, no. 4, pp. 1501-1521, 2022.
, “Alzheimer's Disease with Epileptiform EEG Activity: Abnormal Cortical Sources of Resting State Delta Rhythms in Patients with Amnesic Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 88, no. 3, pp. 903-931, 2022.
, “Anticholinergic Drug Burden and Neurocognitive Performance in the Study of Latinos-Investigation of Neurocognitive Aging.”, J Alzheimers Dis, vol. 86, no. 1, pp. 53-65, 2022.
, “APOEɛ4 Allele Moderates the Association Between Basal Forebrain Nuclei Volumes and Allocentric Navigation in Older Adults Without Dementia.”, J Alzheimers Dis, vol. 86, no. 1, pp. 155-171, 2022.
, “Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds.”, J Alzheimers Dis, vol. 87, no. 4, pp. 1537-1547, 2022.
, “Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds.”, J Alzheimers Dis, vol. 87, no. 4, pp. 1537-1547, 2022.
, “Association of Carotid Intima Media Thickening with Future Brain Region Specific Amyloid-β Burden.”, J Alzheimers Dis, vol. 89, no. 1, pp. 223-232, 2022.
,